Abbott Laboratories highlights diagnostics growth, shares sit in the S&P 500 health cohort
25.06.2026 - 17:26:17 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 17:25.
Abbott Laboratories (US0028241000) remains a core health care name in the S&P 500, with diagnostics and medical devices driving long-term earnings power according to current consensus views. A recent Reuters market overview again listed Abbott among the diversified health care groups watched for defensive growth.
What analysts are pricing in
Wall Street analysts still see Abbott as a diversified earnings story, with a focus on diagnostics, medical devices, nutrition and established pharmaceuticals. MarketBeat data on NYSE-listed Abbott show that a clear majority of brokers rate the shares at Buy or equivalent, while the rest cluster largely in Hold.
Consensus estimates compiled by MarketBeat and other aggregators project mid-single-digit to high-single-digit annual revenue growth over the next few years, underpinned by procedure volumes and chronic disease trends. A recent Motley Fool analysis highlighted Abbott as a steady compounder in the U.S. health care space rather than a short-term momentum stock.
How Abbott compares with peers
In the broader health care sector, Abbott competes with diversified players such as Johnson & Johnson and Medtronic, as well as diagnostics-focused peers like Roche and Thermo Fisher Scientific. Bloomberg’s profile of Abbott notes that the group’s revenue base is more evenly spread across product lines than many pure-play rivals, which can support more stable cash flows through economic cycles.
For U.S. investors, Abbott’s NYSE listing under ticker ABT offers exposure not only to U.S. procedure volumes, but also to emerging-market demand for diagnostics and cardiovascular interventions, an area where consensus expects above-average growth versus more mature portfolios in Europe or Japan.
All news and analysis on the Abbott Laboratories shares
Track recent headlines, estimates and historical data on Abbott Laboratories to see how analysts and markets are valuing the diversified health care group.
The products behind the ticker
Abbott Laboratories generates revenue from a broad range of health care products, with its Alinity family of diagnostic systems, FreeStyle Libre continuous glucose monitoring devices and cardiovascular stents among the most visible offerings for hospitals and patients worldwide.
Where the stock trades today
The Abbott Laboratories shares (US0028241000) trade on the NYSE under the ticker ABT; as of 2026-06-25, 11:13 New York time, they changed hands around 94.40 US dollars.
Key data on the Abbott Laboratories shares
- Company: Abbott Laboratories
- ISIN: US0028241000
- WKN: 850103
- Ticker: ABT
- Trading venue: NYSE
- Price (as of 2026-06-25, 11:13): 94.40 USD
- Market cap: 163 billion USD (as of 2026-06-25)
- Sector / industry: Health Care / Medical Devices & Diagnostics
- Index membership: S&P 500
- Next earnings date: 2026-07-17
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but cannot be guaranteed.
